Last reviewed · How we verify
Placebo for QLS31905 — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo for QLS31905 (Placebo for QLS31905) — Qilu Pharmaceutical Co., Ltd.. This is a placebo control with no active pharmacological mechanism.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo for QLS31905 TARGET | Placebo for QLS31905 | Qilu Pharmaceutical Co., Ltd. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo for QLS31905 CI watch — RSS
- Placebo for QLS31905 CI watch — Atom
- Placebo for QLS31905 CI watch — JSON
- Placebo for QLS31905 alone — RSS
Cite this brief
Drug Landscape (2026). Placebo for QLS31905 — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-for-qls31905. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab